The Lcn2 null mice developed less inflammation due to defects in genes involved in the myeloid cell activation process, and downregulated gene sets for collagen-containing extracellular matrix leading to mitigation of the liver fibrosis. This evidence concerns the gene LCN2 and Hepatic fibrosis.